Several targets showed specifically higher expression in HET cases, including TIM3, BCL2, S100B, and CD44 (tumor ROI only), implying a more immunosuppressive microenvironment within these tumors (Supplemental Figure 7G). The gene discussed is BCL2; the disease is neoplasm.